| Assessment Status | Rapid Review Complete |
| HTA ID | 20041 |
| Drug | Glasdegib |
| Brand | Daurismo® |
| Indication | In combination with LDAC (low-dose cytarabine), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 07/09/2020 |
| Rapid review completed | 09/10/2020 |
| Rapid review outcome | Reimbursement is not recommended at this time, due to a lack of evaluable evidence* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
